{"filings":[{"id":1058756,"accession_number":"0001654954-26-005989","cik":1304161,"company_name":"Pharma-Bio Serv, Inc.","ticker":"PBSV","form_type":"8-K","filed_at":"2026-06-15T21:06:05+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pharma-Bio Serv Q1 revenue $2.7M, net income $0.2M; both up YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Three-month revenue $2.7M, up $0.3M vs prior year; net income $0.2M, up $0.1M.","Six-month revenue $5.0M, up $0.1M; net income $0.3M, up $0.2M.","CEO cites strategic focus on high-return markets and cost management for profit improvement."],"consensus_eps_estimate":null,"consensus_eps_actual":0.012,"consensus_revenue_estimate":null,"consensus_revenue_actual":4997909.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":12939455.629310345,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":472717,"accession_number":"0001654954-26-005006","cik":1304161,"company_name":"Pharma-Bio Serv, Inc.","ticker":"PBSV","form_type":"8-K","filed_at":"2026-05-15T21:02:05+00:00","items":["9.01"],"status":"ready","headline":"Pharma-Bio Serv annual meeting elects Irving Wiesen as Class I director","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Irving Wiesen elected with 10,208,071 votes for and 195,625 withheld; 2,839,645 broker non-votes.","Ratification of Crowe PR PSC as independent auditor for FY ending Oct 31, 2026: 13,241,794 for, 3 against, 1,544 abstain.","No other proposals or material events disclosed at the May 15, 2026 Annual Meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":12939455.629310345,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102479,"accession_number":"0001654954-26-002338","cik":1304161,"company_name":"Pharma-Bio Serv, Inc.","ticker":"PBSV","form_type":"8-K","filed_at":"2026-03-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pharma-Bio Serv Q1 revenue $2.3M, net income $32,860","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of approx. $2.3M, down ~$0.2M from prior year quarter.","Net income of $32,860, an improvement of $24,324 compared to net loss in same quarter last year.","CEO cites improved operational efficiency and disciplined cost management.","Company focuses on sharpening service portfolio and concentrating on highest-value markets."],"consensus_eps_estimate":null,"consensus_eps_actual":0.001,"consensus_revenue_estimate":null,"consensus_revenue_actual":2294966.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":12939455.629310345,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102478,"accession_number":"0001654954-26-000712","cik":1304161,"company_name":"Pharma-Bio Serv, Inc.","ticker":"PBSV","form_type":"8-K","filed_at":"2026-01-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pharma-Bio Serv FY2025 revenue $9.0M (down ~5% YoY), net loss $0.1M; declares $0.075 special dividend","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $9.0M, decrease of $0.5M YoY; net loss $0.1M, improvement of $0.7M from prior year.","Special dividend of $0.075 per share approved; payable March 20, 2026 to holders of record Feb 27, 2026.","CEO cites portfolio rationalization, cost streamlining, and focus on Latin America and Europe for 2026.","Company traded on OTCQB under ticker PBSV; no explicit guidance provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12939455.629310345,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135266,"accession_number":"0001654954-25-010776","cik":1304161,"company_name":"Pharma-Bio Serv, Inc.","ticker":"PBSV","form_type":"8-K","filed_at":"2025-09-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pharma-Bio Serv Q3 revenue $2.0M (down 17% YoY); net loss narrows to $0.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue for three months ended July 31, 2025 was $2.0M, down from $2.4M in the same period last year.","Net loss for Q3 was $0.2M, an improvement of $0.1M compared to a $0.3M loss in Q3 2024.","Nine-month revenue was $6.9M vs $7.2M YoY; net loss $0.1M, improvement of $0.7M.","CEO cites cost streamlining and preparation for imminent start of several significant projects."],"consensus_eps_estimate":null,"consensus_eps_actual":0.004,"consensus_revenue_estimate":null,"consensus_revenue_actual":6851460.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12939455.629310345,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152236,"accession_number":"0001654954-25-007011","cik":1304161,"company_name":"Pharma-Bio Serv, Inc.","ticker":"PBSV","form_type":"8-K","filed_at":"2025-06-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pharma-Bio Serv reports Q2 net income of $0.1M, reversing prior-year loss","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $2.4M (vs $2.3M YoY); six-month revenue $4.9M (vs $4.8M YoY).","Net income for Q2 and first half $0.1M each, up $0.3M and $0.6M vs prior-year losses.","CEO cites focus on high-margin projects as driver of improved profitability.","No guidance provided; OTCQB ticker PBSV remains unchanged."],"consensus_eps_estimate":0.0306,"consensus_eps_actual":0.005,"consensus_revenue_estimate":null,"consensus_revenue_actual":4888377.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12939455.629310345,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152235,"accession_number":"0001654954-25-005812","cik":1304161,"company_name":"Pharma-Bio Serv, Inc.","ticker":"PBSV","form_type":"8-K","filed_at":"2025-05-16T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Pharma-Bio Serv annual meeting elects Howard Spindel, approves say on pay every three years","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Howard Spindel elected Class III director with 7,265,978 votes for, 2,359,070 withheld; 3,264,532 broker non-votes.","Ratification of Crowe PR PSC as auditor for FY25 passed with 12,887,897 votes for, 1,701 against.","Non-binding advisory vote on executive compensation approved: 8,979,762 for, 65,851 against, 579,435 abstain.","Advisory vote on frequency: plurality favored 3 years (6,645,421 votes); company will hold say on pay every three years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":12939455.629310345,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171071,"accession_number":"0001654954-25-002892","cik":1304161,"company_name":"Pharma-Bio Serv, Inc.","ticker":"PBSV","form_type":"8-K","filed_at":"2025-03-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pharma-Bio Serv reports Q1 revenue of $2.5M, near breakeven net income","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue for quarter ended Jan 31, 2025 was ~$2.5M, up ~$0.1M YoY.","Net income near breakeven, an increase of ~$0.3M compared to same quarter last year.","CEO cites net revenue growth in served markets with projects in Europe, Asia, and Latin America."],"consensus_eps_estimate":0.0204,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":2471333.0,"consensus_period":"2025-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":12939455.629310345,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171070,"accession_number":"0001654954-25-000919","cik":1304161,"company_name":"Pharma-Bio Serv, Inc.","ticker":"PBSV","form_type":"8-K","filed_at":"2025-01-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pharma-Bio Serv FY2024 rev $9.5M (-$7.5M YoY), net loss $0.8M; declares $0.075 special dividend","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue for year ended Oct 31, 2024 approximately $9.5M, a decrease of $7.5M from prior year.","Net loss of approximately $0.8M compared to net income of $1.3M in the prior year.","Board approved a Special Dividend of $0.075 per share payable on or about March 20, 2025.","CEO cited challenging industry conditions in 2024; focused on higher-value services and new technologies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12939455.629310345,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171069,"accession_number":"0001654954-25-000918","cik":1304161,"company_name":"Pharma-Bio Serv, Inc.","ticker":"PBSV","form_type":"8-K","filed_at":"2025-01-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Pharma-Bio Serv declares special dividend of $0.075/share payable March 20, 2025","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Special dividend of $0.075 per share approved by the Board of Directors.","Payable on or about March 20, 2025 to shareholders of record at close on February 28, 2025.","Company is a consulting firm serving pharma, biotech, medical device, and related industries."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12939455.629310345,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204548,"accession_number":"0001654954-24-011974","cik":1304161,"company_name":"Pharma-Bio Serv, Inc.","ticker":"PBSV","form_type":"8-K","filed_at":"2024-09-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pharma-Bio Serv Q3 revenue falls to $2.4M, swings to net loss of $0.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $2.4M, down ~$2.2M (48%) from $4.6M in same quarter last year.","Net loss of $0.3M compared to net income of $0.5M in Q3 last year.","Nine-month revenue $7.2M (down $6.2M); net loss $0.8M vs net income $1.4M.","CEO cites challenging investment environment; investing in tech tools to return to profitability."],"consensus_eps_estimate":0.0306,"consensus_eps_actual":0.035,"consensus_revenue_estimate":null,"consensus_revenue_actual":7175967.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12939455.629310345,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221358,"accession_number":"0001654954-24-007798","cik":1304161,"company_name":"Pharma-Bio Serv, Inc.","ticker":"PBSV","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pharma-Bio Serv Q2 revenue down 48% to $2.4M; net loss $0.2M vs income $0.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $2.4M, decline of $2.2M from $4.6M in prior-year quarter.","Net loss $0.2M for the quarter; prior-year period net income was $0.4M.","Six-month revenue $4.8M, down $4.0M; net loss of $0.5M vs income $0.8M.","Management attributing decline to planned FY2024 investments in new client relationships and global events."],"consensus_eps_estimate":0.0306,"consensus_eps_actual":-0.021,"consensus_revenue_estimate":null,"consensus_revenue_actual":4757804.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12939455.629310345,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221357,"accession_number":"0001654954-24-005476","cik":1304161,"company_name":"Pharma-Bio Serv, Inc.","ticker":"PBSV","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Stockholders approve extension of long-term incentive plan to 2034; re-elect two directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved extending the 2014 Long-Term Incentive Plan term to March 31, 2034.","Re-elected Kirk Michel (12.65M votes for) and Dov Perlysky (7.55M votes for) as Class II directors until 2027.","Crowe PR PSC ratified as independent auditor for fiscal year ending Oct 31, 2024 (14.36M for, 1.5K against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":12939455.629310345,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240902,"accession_number":"0001654954-24-003318","cik":1304161,"company_name":"Pharma-Bio Serv, Inc.","ticker":"PBSV","form_type":"8-K","filed_at":"2024-03-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pharma-Bio Serv Q1 revenue down 44% to $2.4M; swings to net loss of $270.7K","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue for Q1 ended Jan 31, 2024: $2.4M, down $1.9M from $4.3M in prior-year quarter.","Net loss of ~$270.7K vs net income of $426.4K in the same quarter last year.","CEO cites planned investments in business development to drive future growth and profitability.","No specific financial guidance or outlook provided for fiscal year 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.012,"consensus_revenue_estimate":null,"consensus_revenue_actual":2380187.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12939455.629310345,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240901,"accession_number":"0001654954-24-001022","cik":1304161,"company_name":"Pharma-Bio Serv, Inc.","ticker":"PBSV","form_type":"8-K","filed_at":"2024-01-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pharma-Bio Serv reports FY2023 revenue $17.0M, net income $1.3M, declares special dividend $0.075/share","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $17.0M, down $2.4M YoY; net income of $1.3M, up $0.3M YoY.","Gross profit margin improved 4.6 percentage points compared to last year.","Special dividend of $0.075/share declared; payable Feb 15, 2024 to holders of record Jan 30, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12939455.629310345,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258406,"accession_number":"0001654954-23-015843","cik":1304161,"company_name":"Pharma-Bio Serv, Inc.","ticker":"PBSV","form_type":"8-K","filed_at":"2023-12-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Pharma-Bio Serv declares special dividend of $0.075 per share, payable Feb 15, 2024","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Board approved a special dividend of $0.075 per share.","Payable on or about February 15, 2024 to shareholders of record January 30, 2024.","Dividend is in addition to any regular quarterly dividend; amount not disclosed.","Company provides compliance and consulting services to pharma, biotech, and allied industries."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12939455.629310345,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275706,"accession_number":"0001654954-23-011895","cik":1304161,"company_name":"Pharma-Bio Serv, Inc.","ticker":"PBSV","form_type":"8-K","filed_at":"2023-09-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pharma-Bio Serv Q3 net income up $0.2M to $0.5M; revenue down $0.2M to $4.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income for Q3 FY2023 (three months ended July 31) was approx $0.5M, up from $0.3M YoY; nine-month net income $1.4M vs $0.9M.","Q3 revenue $4.6M, down from $4.8M YoY; nine-month revenue $13.4M vs $14.8M.","Gross profit margin improved 6.4 percentage points in Q3 and 5.3 percentage points YTD.","CEO Sanchez highlighted successful strategy, new market expansion, and leveraging FDA scrutiny for profitability."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":13378665.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12939455.629310345,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":293268,"accession_number":"0001654954-23-008031","cik":1304161,"company_name":"Pharma-Bio Serv, Inc.","ticker":"PBSV","form_type":"8-K","filed_at":"2023-06-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pharma-Bio Serv Q2 net income rises to $0.4M; revenue falls 8% to $4.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue for three months ended Apr 30, 2023: $4.6M, down $0.4M YoY.","Net income for Q2 was $0.4M, up $0.2M from prior year; H1 net income $0.8M, up $0.3M.","Gross profit margin improved 5.0 percentage points in Q2 and 4.8 ppts in H1.","CEO cites strategy to focus on most profitable markets and grow presence."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":8801498.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":12939455.629310345,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":293267,"accession_number":"0001654954-23-007428","cik":1304161,"company_name":"Pharma-Bio Serv, Inc.","ticker":"PBSV","form_type":"8-K","filed_at":"2023-05-31T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Pharma-Bio Serv elects Irving Wiesen as Class I director at 2023 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Irving Wiesen elected Class I director with 7,477,036 for and 11,696,947 withheld; 515,852 broker non-votes.","Ratification of Crowe PR PSC as auditor for FY ending Oct 31, 2023 passed with 14,344,226 for, 1,492,688 against, 3,852,921 abstain.","Withheld votes exceeded for votes in director election; elected by plurality rule."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":12939455.629310345,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313903,"accession_number":"0001654954-23-003136","cik":1304161,"company_name":"Pharma-Bio Serv, Inc.","ticker":"PBSV","form_type":"8-K","filed_at":"2023-03-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pharma-Bio Serv Q1 2023 revenue $4.2M (-$0.8M YoY); net income $0.4M (+$0.1M YoY)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Quarterly revenue $4.2M, down from $5.0M in prior-year quarter.","Net income $0.4M, compared to $0.3M in same period last year.","CEO cites resource optimization in profitable markets driving gross profit improvement.","Company plans to continue maximizing resources to increase profitability."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":4238356.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12939455.629310345,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}